Treatment modalities for resistant/relapsing gastric mucosa associated lymphoid tissue (MALT) non Hodgkin’s Lymphoma (NHL) are not yet well standardized. In the past most patients were treated surgically with a gastrectomy while more recently radiotherapy (RT) and systemic approaches (chemotherapy and immunotherapy) have been used with improving results.

Here we report the case of a patient affected by MALT NHL resistant to antibiotics chemotherapy and immunotherapy who achieved a durable complete remission after radio-immunotherapy treatment with Zevalin (90Y ibritumomab-tiuxetan) administered in a single standard dose. This observation must be confirmed on a larger series but suggests that radio-immunotherapy may be a valid approach in treating MALT NHL patients relapsing or those resistant to conventional therapies so avoiding more aggressive and toxic approaches.

Further information:

Article source

Related posts:

1. SPECT/CT 90Y-Bremsstrahlung images for dosimetry during therapy
2. Identification of hypoxanthine as a urine marker for non-Hodgkin lymphoma by low-mass-ion profiling
3. The study protocol of the Norwegian randomized controlled trial of electroconvulsive therapy in treatment resistant depression in bipolar disorder.
4. Phase II study of ‘high dose’ celecoxib and metronomic ‘low dose’ cyclophosphamide and methotrexate in patients with relapsed and refactory lymphoma
5. Daptomycin for methicillin-resistant Staphylococcus epidermidis native-valve endocarditis: a case report